clinical trial · NCT07855133
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
Novo Nordisk A/S·phase1·not yet recruiting·n = 60
OverweightObesityType 2 DiabetesSemaglutideZenagamtide
brief summary
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.
started
Sep 30, 2026
primary completion
Sep 6, 2028
completion
Sep 6, 2028
last updated
Oct 2, 2026
official title
An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol